A5075404207- Virus-based gene therapy research
- CAR-T cell therapy research
- Viral Infectious Diseases and Gene Expression in Insects
- Cancer Research and Treatments
- Immunotherapy and Immune Responses
- Glioma Diagnosis and Treatment
- Acute Lymphoblastic Leukemia research
- Research in Cotton Cultivation
- RNA Interference and Gene Delivery
- Cytomegalovirus and herpesvirus research
- interferon and immune responses
- Neuroblastoma Research and Treatments
- Acute Myeloid Leukemia Research
- Venous Thromboembolism Diagnosis and Management
- Fungal Infections and Studies
- Herpesvirus Infections and Treatments
- Cerebral Venous Sinus Thrombosis
- Cutaneous lymphoproliferative disorders research
- Viral Infections and Immunology Research
- Renal and related cancers
- Nanowire Synthesis and Applications
- Cocoa and Sweet Potato Agronomy
- Animal Genetics and Reproduction
- Blood Coagulation and Thrombosis Mechanisms
- Renal cell carcinoma treatment
The University of Texas MD Anderson Cancer Center
2023-2024
Zhengzhou University
2022-2023
Pediatrics and Genetics
2023
The University of Texas Health Science Center at Houston
2023
The BCL-2 inhibitor venetoclax improves survival for adult patients with acute myeloid leukemia (AML) in combination lower-intensity therapies, but its benefit pediatric AML remains unclear. We retrospectively reviewed two Texas Medical Center institutions' experience 43 AML; median age 17 years (range, 0.6-21). This population was highly refractory; 44% of (n = 19) had ≥3 prior lines therapy, 37% 16) received a bone marrow transplant, and 81% 35) unfavorable genetics KMT2A 17), WT1 13),...
Despite advances in treatment options, the clinical outcomes of pediatric patients with advanced solid tumors have hardly improved decades, and alternative options are urgently needed. Innovative therapies, such as chimeric antigen receptor (CAR) T cells oncolytic viruses (OVs), currently being evaluated both adults children refractory tumors. Because remarkably diverse biologically different from their adult counterparts, more research is required to develop effective regimens for these...
Abstract This retrospective study at the University of Texas MD Anderson Cancer Center evaluated frontline venetoclax combination therapy in 11 pediatric/adolescent patients with acute myeloid leukemia (AML). Despite small sample size and nature, treatment demonstrated safety potential efficacy, most achieving early complete remission. Adverse events were consistent other AML therapies, no discontinuations due to toxicity occurred. While acknowledging limitations, including selection bias...
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy, especially in pediatrics, that can involve the bone marrow, skin, lymph nodes, and central nervous system (CNS). Given its variable clinical presentation, coupled with an immunohistochemistry pattern (CD4, CD56, TCF4, TCL-1, CD123 positivity) differs from other myeloid neoplasms, diagnosis of BPDCN be missed. Limited data are available to guide treatment pediatric BPDCN. Herein, we report case patient who...
In this study, a total of 66 UDP-glucose pyrophosphorylase (UGP) (EC 2.7.7.9) genes were identified from the genomes four cotton species, which are members Pfam glycosyltransferase family (PF01702) and catalyze reaction between glucose-1-phosphate UTP to produce UDPG. The analysis evolutionary relationship, gene structure, expression provides basis for studies on function UGP in cotton. tree structure revealed that is evolutionarily conserved. Collinearity Ka/Ks indicated amplification due...
<h3>Background</h3> Viroimmunotherapy has emerged as a promising strategy to treat patients with glioblastoma (GBM). Our group developed Delta-24-RGD, an oncolytic adenovirus that been tested in clinical trials for adult and pediatric brain tumors showing encouraging 20% response.<sup>1–3</sup> The dual mechanism of action the viruses encompasses direct tumor cell lysis indirect anti-tumor immune response. To improve rate responses, we generated Delta-24-RGDOX, armed version expressing...
<h3>Background</h3> Glioblastoma multiforme (GBM) is the most common primary malignancy of central nervous system. GBM patients often face dismal prognoses despite aggressive treatments, highlighting urgent need for innovative therapeutic approaches. Oncolytic virotherapy (OV) utilizing Delta-24-RGD has emerged as a promising strategy, with recent clinical trials (NCT00805376, NCT03178032, and NCT02798406)<sup>1–3</sup> showing encouraging responses in subsets patients. However, several...
<h3>Background</h3> To address the unmet medical needs for patients with advanced metastatic solid tumors, CAR T cells and oncolytic viruses (OVs) are being tested clinically. Unlike their remarkable success in hemopoietic malignancies, effect of tumors is moderate. We have reported that third-generation adenovirus (OA), Delta-24-RGDOX, which expresses immune co-stimulator OX40 ligand (OX40L), more potent to elicit anti-tumor immunity than second-generation OA Delta-24-RGD sustains systemic...
12117 Background: ICIs are increasingly used in AYAs with cancer, however, limited data exists on the frequency and pattern of irAEs this population ability to rechallenge after irAEs. Methods: This retrospective study analyzed aged 15-39 melanoma who received treatment at MD Anderson Cancer Center from 2013 2023. Treatment cessation was defined as switching therapies or pausing original for over 3 months, resuming immunotherapy post-cessation. Results: A total 136 pts were included, 80 male...
Abstract BACKGROUND Diffuse intrinsic pontine glioma (DIPG) occurs exclusively in children and, although rare, carries a poor prognosis with median survival of approximately 10 months. Diagnosis is made on clinical and radiological appearance the tumor. The treatment for DIPG radiation therapy, but it inadequate as most patients experience rapid progression succumb to disease. Our study sought review characteristics outcomes pediatric at MD Anderson Cancer Center better understand imaging...
Abstract BACKGROUND Diffuse leptomeningeal glioneuronal tumors (DLGNTs) are extremely rare that were first described in the WHO Classification 2016. While usually considered low-grade tumors, DLGNTs currently lack a standard of care as well literature on molecular profiling and treatment responses. METHODS Retrospective review pediatric seen at MD Anderson Cancer Center with Institutional Board Review approval. RESULTS Twelve patients histopathological neuroradiological diagnosis DLGNT...
Abstract BACKGROUND H3K27-altered pediatric diffuse midline glioma (DMG) is a highly aggressive type of brain tumor with 5-year survival rate less than 2%. Conventional treatments are restricted to palliative radiation therapy. Therefore, effective urgently needed. Results from recent phase I clinical trial for Diffuse Intrinsic Pontine Glioma showed that intratumoral administration Delta-24-RGD oncolytic adenovirus in combination improves without unwanted toxicity. Based on the rationale...
<h3>Background</h3> Viroimmunotherapy is an emerging biotherapeutic strategy utilizing oncolytic viruses (OVs) to mediate tumor destruction through direct oncolysis and instigation of anti-tumor immunity. There growing interest in viroimmunotherapy for pediatric brain tumors due its ability enhance immune responses non-inflamed tumors. Our lab developed the adenovirus Delta-24-RGD, which has been tested Phase I clinical trial (NCT03178032) as front-line therapy brainstem diffuse midline...
<h3>Background</h3> Previous trials testing oncolytic adenovirus Delta-24-RGD in malignant gliomas has shown encouraging results. Since viruses can stimulate immune reactions against both virus and tumor, immunodominance of viral antigens may prevent the preferred generation tumor-specific clones. In this work, we tested extent to which nanoparticle-induced tolerance shift focus system tumor improves therapeutic outcome. <h3>Methods</h3> Genomic DNA from surgical samples 9 glioma patients...
<h3>Background</h3> Oncolytic virotherapy is a special case of cancer immunotherapy that mounts significant inflammatory immune response along with oncolysis. We recently demonstrated Delta-24-RGD, an oncolytic adenovirus, can be safely combined radiotherapy to treat pediatric Diffuse Intrinsic Pontine Glioma in phase I clinical trial (NCT03178032). In this trial, combining Delta-24-RGD increased the median survival patients 17.8 months. Histone hyperacetylation epigenetic signature Midline...
Abstract Diffuse midline glioma (DMG) remains a devastating pediatric brain tumor without effective treatment. In recent clinical trial, we demonstrated the feasibility and efficacy of Delta-24-RGD oncolytic virus combined with radiation therapy in patients newly diagnosed diffuse intrinsic pontine gliomas (NCT03178032). Because adenoviral protein E1A binds to P300 redirects acetylation upon infection, hypothesized that combining adenoviruses inhibitors will cause remarkable shifting...
Abstract Phase 1 and 2 clinical trials of our oncolytic adenovirus Delta-24-RGD for patients with recurrent malignant gliomas have demonstrated its safety efficacy, showed that 20% the experienced long-term tumor remissions often associated inflammatory responses infiltration lymphocytes. Based on preliminary data, we expected most frequent tumor-infiltrating CD8+ T cell clones will target adenoviral hexon, a single virus-specific clone representing up to 5% total population. Competition...
Abstract Diffuse midline gliomas (DMGs) are among the most frequent and lethal pediatric tumors. The standard of care for DMGs is palliative, resulting in a median survival 12 months. Viroimmunotherapy an emerging alternative treatment these Our group developed platform oncolytic adenoviruses that was translated to clinic. Specifically, Delta-24-RGD recently tested Phase I clinical trial patients with newly diagnosed DMG (NCT03178032) encouraging results. To further stimulate immune arm this...
Abstract Glioblastoma (GBM) poses a significant therapeutic challenge in oncology. Recent clinical trials have shown the feasibility of virotherapy to treat patients with GBM. Our laboratory developed an oncolytic adenovirus termed Delta-24-RGD that has been tested for recurrent GBM encouraging results (NCT00805376, NCT02798406). These studies, together preclinical data, showed efficacy was due direct tumor cell oncolysis and indirect activation anti-tumor immune response. To further...
Abstract Accumulating evidence show that the interaction between oncolytic viruses (OVs) and host immune system plays an essential role in cancer virotherapy. Compared to lytic potency of OVs, enhancement OV-mediated anti-tumor immunity has become a more attractive strategy improve OV efficacy. To this end, we have reported third-generation adenovirus (OA), Delta-24-RGDOX, which expresses co-stimulator OX40 ligand (OX40L), is potent elicit than second-generation OA Delta-24-RGD. Since IL-15...